US2015011405A1PendingUtilityA1

Use of Nanoexpression to Interrogate Antigen Repertoires

Assignee: ATRECA INCPriority: Jul 3, 2013Filed: Jun 30, 2014Published: Jan 8, 2015
Est. expiryJul 3, 2033(~6.9 yrs left)· nominal 20-yr term from priority
G01N 33/6854C40B 30/04
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed herein are methods and compositions for using nanoexpression to interrogate antigen specificity within antibody repertoires. Also disclosed herein is an antibody display system composition comprising one or more recombinant nucleic acid sequences comprising a first nucleic acid sequence encoding a heavy chain variable region sequence or fragment thereof operatively linked to a first identification region sequence and a second nucleic acid sequence encoding a light chain variable region sequence or fragment thereof operatively linked to a second identification region sequence.

Claims

exact text as granted — not AI-modified
1 . An antibody display system composition comprising one or more recombinant nucleic acid sequences comprising a first nucleic acid sequence encoding a heavy chain variable region sequence or fragment thereof operatively linked to a first identification region sequence and a second nucleic acid sequence encoding a light chain variable region sequence or fragment thereof operatively linked to a second identification region sequence. 
     
     
         2 . The composition of  claim 1 , wherein the first and second identification region sequences are distinct. 
     
     
         3 . The composition of  claim 1 , wherein the first and second identification region sequences are identical. 
     
     
         4 . The composition of  claim 1 , wherein the one or more recombinant nucleic acid sequences comprises a Fab sequence. 
     
     
         5 . The composition of  claim 1 , wherein the one or more recombinant nucleic acid sequences comprises a scFv sequence. 
     
     
         6 . The composition of  claim 1 , wherein the antibody display system composition is a phagemid. 
     
     
         7 . The composition of  claim 1 , wherein the antibody display system composition is a ribosome, cell, mRNA, mammalian cell, bacteria, or yeast cell. 
     
     
         8 . An antibody display system library comprising a plurality of the antibody display system composition of  claim 1 . 
     
     
         9 . A method of annotating an antibody display system library with binding data, comprising:
 obtaining the library of  claim 8  bound to an antigen of interest, wherein the sequences used to construct the library were known;   determining a dataset comprising binding data and sequence data for the library; and   annotating the library with the data of the dataset using the sequence data and the known sequences used to construct the library.   
     
     
         10 . A method of annotating an antibody repertoire, comprising:
 obtaining a first dataset, wherein the first dataset comprises sequence data for a plurality of heavy and light chain antibody sequence pairs each from a distinct single sample, wherein each sequence of each pair is operatively linked to an identification region sequence, and wherein each identification region sequence is unique relative to the other identification region sequences within the plurality;   creating an antibody display system using the dataset, wherein the antibody display system comprises a plurality of components;   binding the antibody display system to an antigen;   determining a second dataset comprising binding data and sequence data based on the binding step; and   annotating the sequence data of the first dataset with the data of the second dataset.   
     
     
         11 . The method of  claim 10 , wherein the antibody display system is the library of  claim 8 . 
     
     
         12 . The method of  claim 10 , wherein the single sample is a single B cell. 
     
     
         13 . The method of  claim 10 , wherein the binding data is affinity data. 
     
     
         14 . The method of  claim 10 , wherein the binding data is antigen-specificity data. 
     
     
         15 . The method of  claim 10 , wherein the binding data is determined using an ELISA assay. 
     
     
         16 . The method of  claim 10 , wherein the sequence data of the second dataset is determined using sequencing. 
     
     
         17 . The method of  claim 10 , wherein the sequence data of the second dataset is determined using next generation sequencing (NGS). 
     
     
         18 . The method of  claim 10 , wherein the antigen is a recombinant protein, a cell, a subcellular fraction, a bacterium, fungi, protozoa, or a tissue. 
     
     
         19 . The method of  claim 10 , wherein the sequence data of the second dataset comprises sequence data for a plurality of heavy and light chain antibody sequences, wherein each sequence is operatively linked to an identification region sequence. 
     
     
         20 . The method of  claim 10 , wherein the sequence data of the first dataset is annotated with the binding data of the second dataset by comparison of the identification region sequence data of the first dataset to the identification region sequence data of the second dataset.

Join the waitlist — get patent alerts

Track US2015011405A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.